GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?

References

• Danaei G Finucane MM Lu Y National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants Lancet 2011 378 9785 31 40 21705069
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going Am J Med 2010 123 Suppl 3 S38 S48 20206731
   PubMed Web of Science ®Google Scholar
• Colagiuri S Dickinson S Girgis S Colagiuri R National evidence-based guideline for blood glucose control in type 2 diabetes Canberra, Australia Diabetes Australia and the National Health and Medical Research Council 2009 Available from: https://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/di19-diabetes-blood-glucose-control.pdf Accessed April 3, 2014
   Google Scholar
• Bailey T Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm Am J Med 2013 126 9 Suppl 1 S10 S20 23953074
   PubMed Web of Science ®Google Scholar
• Boland CL Degeeter M Nuzum DS Tzefos M Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors Ann Pharmacother 2013 47 4 490 505 23548652
   PubMed Web of Science ®Google Scholar
• Baggio LL Drucker DJ Biology of incretins: GLP-1 and GIP Gastroenterology 2007 132 6 2131 2157 17498508
   PubMed Web of Science ®Google Scholar
• Nauck MA Holst JJ Willms B Schmiegel W Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes Exp Clin Endocrinol Diabetes 1997 105 4 187 195 9285204
   PubMed Web of Science ®Google Scholar
• Bloomgarden ZT Blonde L Garber AJ Wysham CH Current issues in GLP-1 receptor agonist therapy for type 2 diabetes Endocr Pract 2012 18 Suppl 3 6 26 23315305
   PubMed Web of Science ®Google Scholar
• Drucker DJ Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls Diabetes 2013 62 10 3316 3323 23818527
   PubMed Web of Science ®Google Scholar
• Cernea S Raz I Therapy in the early stage: incretins Diabetes Care 2011 34 Suppl 2 S264 S271 21525466
   PubMed Web of Science ®Google Scholar
• Drucker DJ The biology of incretin hormones Cell Metab 2006 3 3 153 165 16517403
   PubMed Web of Science ®Google Scholar
• Orskov C Rabenhøj L Wettergren A Kofod H Holst JJ Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans Diabetes 1994 43 4 535 539 8138058
   PubMed Web of Science ®Google Scholar
• Deacon CF Johnsen AH Holst JJ Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo J Clin Endocrinol Metab 1995 80 3 952 957 7883856
   PubMed Web of Science ®Google Scholar
• Pabreja K Mohd MA Koole C Wootten D Furness SG Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation Br J Pharmacol 2014 171 5 1114 1128 23889512
   PubMed Web of Science ®Google Scholar
• Tomas E Habener JF Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis Trends Endocrinol Metab 2010 21 2 59 67 20018525
   PubMed Web of Science ®Google Scholar
• Liu Z Stanojevic V Brindamour LJ Habener JF GLP1-derived nonapeptide GLP1(28–36)amide protects pancreatic β-cells from glucolipotoxicity J Endocrinol 2010 21 2 59 67
   Google Scholar
• Shao W Wang Z Ip W GLP-1(28-36) improves β-cell mass and glucose disposal in streptozotocin induced diabetes mice and activates PKA-β-catenin signaling in beta-cells in vitro Am J Physiol Endocrinol Metab 2013 304 12 E1263 E1272 23571712
   PubMed Web of Science ®Google Scholar
• Mundil D Beca S Cameron-Vendrig A GLP-1[28–36] exerts direct cardioprotective effects, activating pro-survival kinases and soluble adenylyl cyclase Circulation 2012 126 Abstr 13657
   Web of Science ®Google Scholar
• Tomas E Wood JA Stanojevic V Habener JF GLP-1-derived nonapeptide GLP-1(28–36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice Regul Pept 2011 169 1–3 43 48 21549160
   PubMedGoogle Scholar
• Tomas E Stanojevic V Habener JF GLP-1-derived nonapeptide GLP-1(28–36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes Regul Pept 2011 167 2–3 177 184 21256872
   PubMedGoogle Scholar
• Nikolaidis LA Doverspike A Hentosz T Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines J Pharmacol Exp Ther 2005 312 1 303 308 15356213
   PubMed Web of Science ®Google Scholar
• Meier JJ Gethmann A Nauck MA The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans Am J Physiol Endocrinol Metab 2006 290 6 E1118 E1123 16403774
   PubMed Web of Science ®Google Scholar
• Elahi D Egan JM Shannon RP GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide Obesity (Silver Spring) 2008 16 7 1501 1509 18421270
   PubMed Web of Science ®Google Scholar
• Ban K Noyan-Ashraf MH Hoefer J Bolz SS Drucker DJ Husain M Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways Circulation 2008 117 18 2340 2350 18427132
   PubMed Web of Science ®Google Scholar
• Ban K Kim KH Cho CK Glucagon-like peptide (GLP)-1(9-36) amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor Endocrinology 2010 151 4 1520 1531 20172966
   PubMed Web of Science ®Google Scholar
• Ruiz-Grande C Alarcón C Alcántara A Renal catabolism of truncated glucagon-like peptide 1 Horm Metab Res 1993 25 12 612 616 8119664
   PubMed Web of Science ®Google Scholar
• Meier JJ Nauck MA Kranz D Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects Diabetes 2004 53 3 654 662 14988249
   PubMed Web of Science ®Google Scholar
• Koole C Pabreja K Savage EE Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function Biochem Soc Trans 2013 41 1 172 179 23356279
   PubMed Web of Science ®Google Scholar
• Brubaker PL Drucker DJ Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors Receptors Channels 2002 8 3–4 179 188 12529935
   PubMedGoogle Scholar
• Scrocchi LA Brown TJ MaClusky N Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene Nat Med 1996 2 11 1254 1258 8898756
   PubMed Web of Science ®Google Scholar
• Knudsen LB Nielsen PF Huusfeldt PO Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration J Med Chem 2000 43 9 1664 1669 10794683
   PubMed Web of Science ®Google Scholar
• Agersø H Jensen LB Elbrønd B Rolan P Zdravkovic M The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men Diabetologia 2002 45 2 195 202 11935150
   PubMed Web of Science ®Google Scholar
• Parkes DG Mace KF Trautmann ME Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1 Expert Opin Drug Discov 2013 8 2 219 244 23231438
   PubMed Web of Science ®Google Scholar
• Drucker DJ Buse JB Taylor K Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 2008 372 9645 1240 1250 18782641
   PubMed Web of Science ®Google Scholar
• Rosenstock J Balas B Charbonnel B The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-Emerge 2 trial Diabetes Care 2013 36 3 498 504 23139373
   PubMed Web of Science ®Google Scholar
• Noel RA Braun DK Patterson RE Bloomgren GL Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study Diabetes Care 2009 32 5 834 838 19208917
   PubMed Web of Science ®Google Scholar
• Dore DD Seeger JD Arnold Chan K Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide Curr Med Res Opin 2009 25 4 1019 1027 19278373
   PubMed Web of Science ®Google Scholar
• Dore DD Bloomgren GL Wenten M A cohort study of acute pancreatitis in relation to exenatide use Diabetes Obes Metab 2011 13 6 559 566 21320263
   PubMed Web of Science ®Google Scholar
• Williams-Herman D Round E Swern AS Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis BMC Endocr Disord 2008 8 14 18954434
   PubMedGoogle Scholar
• White J Efficacy and safety of incretin based therapies: clinical trial data J Am Pharm Assoc (2003) 2009 49 Suppl 1 S30 S40 19801363
   PubMed Web of Science ®Google Scholar
• Montanya E Sesti G A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus Clin Ther 2009 31 11 2472 2488 20109994
   PubMed Web of Science ®Google Scholar
• Garg R Chen W Pendergrass M Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis Diabetes Care 2010 33 11 2349 2354 20682680
   PubMed Web of Science ®Google Scholar
• Elashoff M Matveyenko AV Gier B Elashoff R Butler PC Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies Gastroenterology 2011 141 1 150 156 21334333
   PubMed Web of Science ®Google Scholar
• Singh S Chang HY Richards TM Weiner JP Clark JM Segal JB Glucagon-like peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study JAMA Intern Med 2013 173 7 534 539 23440284
   PubMed Web of Science ®Google Scholar
• Wenten M Gaebler JA Hussein M Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study Diabet Med 2012 29 11 1412 1418 22416857
   PubMed Web of Science ®Google Scholar
• Macconell L Brown C Gurney K Han J Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials Diabetes Metab Syndr Obes 2012 5 29 41 22375098
   PubMedGoogle Scholar
• Butler AE Campbell-Thompson M Gurlo T Dawson DW Atkinson M Butler PC Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors Diabetes 2013 62 7 2595 2604 23524641
   PubMed Web of Science ®Google Scholar
• Nauck MA A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks Diabetes Care 2013 36 7 2126 2132 23645884
   PubMed Web of Science ®Google Scholar
• Butler PC Elashoff M Elashoff R Gale EA A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013 36 7 2118 2125 23645885
   PubMed Web of Science ®Google Scholar
• Samson SL Garber A GLP-1R agonist therapy for diabetes: benefits and potential risks Curr Opin Endocrinol Diabetes Obes 2013 20 2 87 97 23403741
   PubMedGoogle Scholar
• Tomas E Stanojevic V Habener JF GLP-1(9-36) amide metabolite suppression of glucose production in isolated mouse hepatocytes Horm Metab Res 2010 42 9 657 662 20645222
   PubMed Web of Science ®Google Scholar
• Sonne DP Engstrøm T Treiman M Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia-reperfusion injury in rat heart Regul Pept 2008 146 1–3 243 249 17976835
   PubMed Web of Science ®Google Scholar
• Sathananthan M Farrugia LP Miles JM Direct effects of exendin-(9,39) and GLP-1-(9,36)amide on insulin action, beta-cell function, and glucose metabolism in nondiabetic subjects Diabetes 2013 62 8 2752 2756 23545708
   PubMed Web of Science ®Google Scholar
• Plamboeck A Holst JJ Carr RD Deacon CF Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig Diabetologia 2005 48 9 1882 1890 16025254
   PubMed Web of Science ®Google Scholar
• Ip W Shao W Chiang YT Jin T GLP-1-derived nonapeptide GLP-1(28-36)amide represses hepatic gluconeogenic gene expression and improves pyruvate tolerance in high fat diet fed mice Am J Physiol Endocrinol Metab 2013 305 11 E1348 E1358 24085036
   PubMed Web of Science ®Google Scholar
• Sharma R McDonald TS Eng H In vitro metabolism of the glucagon-like peptide-1 (GLP-1)-derived metabolites GLP-1(9-36) amide and GLP-1(28-36)amide in mouse and human hepatocytes Drug Metab Dispos 2013 41 12 2148 2157 24056839
   PubMed Web of Science ®Google Scholar
• McGirr R Ejbick CE Carter DE Glucose dependence of the regulated secretory pathway in alphaTC1-6 cells Endocrinology 2005 146 10 4514 4523 15994347
   PubMed Web of Science ®Google Scholar
• Whalley NM Pritchard LE Smith DM White A Processing of proglucagon to GLP-1 in pancreatic alpha-cells: is this a paracrine mechanism enabling GLP-1 to act on beta-cells? J Endocrinol 2011 211 1 99 106 21795304
   PubMed Web of Science ®Google Scholar
• Zraika S Hull RL Udayasankar J Identification of the amyloid-degrading enzyme neprilysin in mouse islets and potential role in islet amyloidogenesis Diabetes 2007 56 2 304 310 17259373
   PubMed Web of Science ®Google Scholar
• Butler AA Kozak LP A recurring problem with the analysis of energy expenditure in genetic models expressing lean and obese phenotypes Diabetes 2010 59 2 323 329 20103710
   PubMed Web of Science ®Google Scholar
• Tschöp MH Speakman JR Arch JR A guide to analysis of mouse energy metabolism Nat Methods 2012 9 1 57 63 22205519
   PubMed Web of Science ®Google Scholar
• Turner N Kowalski GM Leslie SJ Distinct patterns of tissue-specific lipid accumulation during the induction of insulin resistance in mice by high-fat feeding Diabetologia 2013 56 7 1638 1648 23620060
   PubMed Web of Science ®Google Scholar
• Ryu H Lee J Impey S Ratan RR Ferrante RJ Antioxidants modulate mitochondrial PKA and increase CREB binding to D-loop DNA of the mitochondrial genome in neurons Proc Natl Acad Sci U S A 2005 102 39 13915 13920 16169904
   PubMed Web of Science ®Google Scholar
• Alarcon C Wicksteed B Rhodes CJ Exendin 4 controls insulin production in rat islet beta cells predominantly by potentiation of glucose-stimulated proinsulin biosynthesis at the translational level Diabetologia 2006 49 12 2920 2929 17053883
   PubMed Web of Science ®Google Scholar
• Ebinger M Jehle DR Fussgaenger RD Fehmann HC Jehle PM Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes Am J Physiol Endocrinol Metab 2000 279 1 E88 E94 10893327
   PubMed Web of Science ®Google Scholar
• Stumvoll M Fritsche A Stefan N Hardt E Häring H Evidence against a rate-limiting role of proinsulin processing for maximal insulin secretion in subjects with impaired glucose tolerance and beta-cell dysfunction J Clin Endocrinol Metab 2001 86 3 1235 1239 11238514
   PubMed Web of Science ®Google Scholar
• Faradji RN Froud T Messinger S Long-term metabolic and hormonal effects of exenatide on islet transplant recipients with allograft dysfunction Cell Transplant 2009 18 10 1247 1259 20003758
   PubMed Web of Science ®Google Scholar
• Rosenstock J Brazg R Andryuk PJ Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Clin Ther 2006 28 10 1556 1568 17157112
   PubMed Web of Science ®Google Scholar
• Nauck MA Heimesaat MM Orskov C Holst JJ Ebert R Creutzfeldt W Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus J Clin Invest 1993 91 1 301 307 8423228
   PubMed Web of Science ®Google Scholar
• Kolterman OG Buse JB Fineman MS Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes J Clin Endocrinol Metab 2003 88 7 3082 3089 12843147
   PubMed Web of Science ®Google Scholar
• Juhl CB Hollingdal M Sturis J Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes Diabetes 2002 51 2 424 429 11812750
   PubMed Web of Science ®Google Scholar
• Ahrén B Landin-Olsson M Jansson PA Svensson M Holmes D Schweizer A Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes J Clin Endocrinol Metab 2004 89 5 2078 2084 15126524
   PubMed Web of Science ®Google Scholar
• Buteau J Foisy S Rhodes CJ Carpenter L Biden TJ Prentki M Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation Diabetes 2001 50 10 2237 2243 11574404
   PubMed Web of Science ®Google Scholar
• Xu G Stoffers DA Habener JF Bonner-Weir S Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats Diabetes 1999 48 12 2270 2276 10580413
   PubMed Web of Science ®Google Scholar
• Mu J Woods J Zhou YP Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes Diabetes 2006 55 6 1695 1704 16731832
   PubMed Web of Science ®Google Scholar
• Li Y Hansotia T Yusta B Ris F Halban PA Drucker DJ Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis J Biol Chem 2003 278 1 471 478 12409292
   PubMed Web of Science ®Google Scholar
• Hui H Nourparvar A Zhao X Perfetti R Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway Endocrinology 2003 144 4 1444 1455 12639928
   PubMed Web of Science ®Google Scholar
• Li Y Cao X Li LX Brubaker PL Edlund H Drucker DJ beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1 Diabetes 2005 54 2 482 491 15677506
   PubMed Web of Science ®Google Scholar
• Pospisilik JA Martin J Doty T Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats Diabetes 2003 52 3 741 750 12606516
   PubMed Web of Science ®Google Scholar
• Svegliati-Baroni G Saccomanno S Rychlicki C Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis Liver Int 2011 31 9 1285 1297 21745271
   PubMed Web of Science ®Google Scholar
• Prigeon RL Quddusi S Paty B D’Alessio DA Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect Am J Physiol Endocrinol Metab 2003 285 4 E701 E707 12773303
   PubMed Web of Science ®Google Scholar
• Valverde I Morales M Clemente F Glucagon-like peptide 1: a potent glycogenic hormone FEBS Lett 1994 349 2 313 316 8050588
   PubMed Web of Science ®Google Scholar
• Wettergren A Schjoldager B Mortensen PE Myhre J Christiansen J Holst JJ Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man Dig Dis Sci 1993 38 4 665 673 8462365
   PubMed Web of Science ®Google Scholar
• Kolterman OG Kim DD Shen L Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus Am J Health Syst Pharm 2005 62 2 173 181 15700891
   PubMed Web of Science ®Google Scholar
• Bose AK Mocanu MM Carr RD Brand CL Yellon DM Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury Diabetes 2005 54 1 146 151 15616022
   PubMed Web of Science ®Google Scholar
• Okerson T Chilton RJ The cardiovascular effects of GLP-1 receptor agonists Cardiovasc Ther 2012 30 3 e146 e155 21167014
   PubMed Web of Science ®Google Scholar
• Chinda K Palee S Surinkaew S Phornphutkul M Chattipakorn S Chattipakorn N Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury Int J Cardiol 2013 167 2 451 457 22285447
   PubMed Web of Science ®Google Scholar
• Flint A Raben A Astrup A Holst JJ Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans J Clin Invest 1998 101 3 515 520 9449682
   PubMed Web of Science ®Google Scholar
• Szayna M Doyle ME Betkey JA Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats Endocrinology 2000 141 6 1936 1941 10830274
   PubMed Web of Science ®Google Scholar
• Langley AK Suffoletta TJ Jennings HR Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus Pharmacotherapy 2007 27 8 1163 1180 17655515
   PubMed Web of Science ®Google Scholar
• Zander M Madsbad S Madsen JL Holst JJ Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study Lancet 2002 359 9309 824 830 11897280
   PubMed Web of Science ®Google Scholar
• Buse JB Henry RR Han J Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes Diabetes Care 2004 27 11 2628 2635 15504997
   PubMed Web of Science ®Google Scholar
• Nauck MA Hompesch M Filipczak R Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes Exp Clin Endocrinol Diabetes 2006 114 8 417 423 17039422
   PubMed Web of Science ®Google Scholar
• Ahrén B Gomis R Standl E Mills D Schweizer A Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes Diabetes Care 2004 27 12 2874 2880 15562200
   PubMed Web of Science ®Google Scholar
• Perry T Haughey NJ Mattson MP Egan JM Greig NH Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4 J Pharmacol Exp Ther 2002 302 3 881 888 12183643
   PubMed Web of Science ®Google Scholar
• D’Amico M Di Filippo C Marfella R Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer’s prone mice Exp Gerontol 2010 5 3 202 207 20005285
   PubMed Web of Science ®Google Scholar
• Therapeutic Goods Administration Australian public assessment report for exenatide Canberra, ACT, Australia Australian Government Department of Health and Ageing 2013 Available from: http://www.tga.gov.au/pdf/auspar/auspar-exenatide-130205-1.pdf Accessed April 4, 2014
   Google Scholar
• Therapeutic Goods Administration Product information for Byetta (exenatide) Canberra, ACT, Australia Australian Government Department of Health and Ageing 2013 Available from: http://www.tga.gov.au/pdf/auspar/auspar-exenatide-130603-pi.pdf Accessed April 4, 2014
   Google Scholar
• Therapeutic Goods Administration Product information for AusPAR Byetta and Bydureon (exenatide) Canberra, ACT, Australia Australian Government Department of Health and Ageing 2013 Available from: http://www.tga.gov.au/pdf/auspar/auspar-exenatide-130205-pi.pdf Accessed April 4, 2014
   Google Scholar
• Therapeutic Goods Administration Australian Public Assessment Report for Liraglutide (rys) Canberra, ACT, Australia Australian Government Department of Health and Ageing 2010 Available from: http://www.tga.gov.au/pdf/auspar/auspar-victoza.pdf Accessed April 4, 2014
   Google Scholar
• Therapeutic Goods Administration Product information for AusPAR Lyxumia/Lyxumia Canberra, ACT, Australia Australian Government Department of Health and Ageing 2010 Available from: http://www.tga.gov.au/pdf/auspar/auspar-lixisenatide-130820-pi.pdf Accessed April 4, 2014
   Google Scholar
• Therapeutic Goods Administration Australian Public Assessment Report for Alogliptin (as benzoate) Canberra, ACT, Australia Australian Government Department of Health and Ageing 2014 Available from: http://www.tga.gov.au/pdf/auspar/auspar-alogliptin-benzoate-140109.pdf Accessed April 4, 2014
   Google Scholar
• Therapeutic Goods Administration Australian Public Assessment Report for Linagliptin Canberra, ACT, Australia Australian Government Department of Health and Ageing 2011 Available from: https://www.tga.gov.au/pdf/auspar/auspar-linagliptin-130926.pdf Accessed April 4, 2014
   Google Scholar
• Therapeutic Goods Administration Product information for AusPAR Trajenta Linagliptin Canberra, ACT, Australia Australian Government Department of Health and Ageing 2013 Available from: http://www.tga.gov.au/pdf/auspar/auspar-linagliptin-130926-pi.pdf Accessed April 4, 2014
   Google Scholar
• Therapeutic Goods Administration Australian Public Assessment Report for saxagliptin hydrochloride Canberra, ACT, Australia Australian Government Department of Health and Ageing 2011 Available from: http://www.tga.gov.au/pdf/auspar/auspar-onglyza.pdf Accessed April 4, 2014
   Google Scholar
• Therapeutic Goods Administration Product information for AusPAR Onglyza saxagliptin Canberra, ACT, Australia Australian Government Department of Health and Ageing 2011 Available from: https://www.tga.gov.au/pdf/auspar/auspar-saxagliptin-130313-pi.pdf Accessed April 4, 2014
   Google Scholar
• Therapeutic Goods Administration Australian Public Assessment Report for sitagliptin (as phosphate monohydrate) Canberra, ACT, Australia Australian Government Department of Health and Ageing 2012 Available from: https://www.tga.gov.au/pdf/auspar/auspar-sitagliptin-121220.pdf Accessed April 4, 2014
   Google Scholar
• Therapeutic Goods Administration Product information for AusPAR Januvia sitagliptin Canberra, ACT, Australia Australian Government Department of Health and Ageing 2012 Available from: http://www.tga.gov.au/pdf/auspar/auspar-sitagliptin-121220-pi.pdf Accessed April 4, 2014
   Google Scholar
• Therapeutic Goods Administration Australian Public Assessment Report for vildagliptin Canberra, ACT, Australia Australian Government Department of Health and Ageing 2010 Available from: http://www.tga.gov.au/pdf/auspar/auspar-galvus.pdf Accessed April 4, 2014
   Google Scholar
• Furuta S Smart C Hackett A Benning R Warrington S Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans Xenobiotica 2013 43 5 432 442 23075005
   PubMed Web of Science ®Google Scholar
• Kadowaki T Kondo K Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus Diabetes Obes Metab 2013 4 6 576 584
   Google Scholar
• Yang SJ Min KW Gupta SK A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes Diabetes Obes Metab 2013 15 5 410 416 23170990
   PubMed Web of Science ®Google Scholar
• Kim N Patrick L Mair S Absorption, metabolism and excretion of [C]gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans Xenobiotica 12 4 2013 [Epub ahead of print.]
   Web of Science ®Google Scholar
• Kim SH Lee SH Yim HJ Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry Arch Pharm Res 2013 36 10 1185 1188 23771499
   PubMed Web of Science ®Google Scholar
• Egan AG Blind E Dunder K Pancreatic safety of incretin-based drugs – FDA and EMA assessment N Engl J Med 2014 370 9 794 797 24571751
   PubMed Web of Science ®Google Scholar